2014 update on atopic dermatitis in children

Current Opinion in Pediatrics

Volumn 26, Issue 4, 2014, Pages 466-471

  Totri, Christine R ^a,b   Diaz, Lucia ^a,b   Eichenfield, Lawrence F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

atopic dermatitis; atopic march; filaggrin mutations; topical calcineurin inhibitors; topical corticosteroids

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; BLEACHING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; FILAGGRIN; INTERMEDIATE FILAMENT PROTEIN;

ATOPIC DERMATITIS; ATTENTION DEFICIT DISORDER; BATH; CHRONIC DISEASE; CLINICAL RESEARCH; COMORBIDITY; DEVELOPED COUNTRY; ENVIRONMENTAL FACTOR; HUMAN; IMMUNOLOGIST; MEDICAL SPECIALIST; PATHOPHYSIOLOGY; PEDIATRICIAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; CHILD; CLINICAL PRACTICE; DERMATITIS, ATOPIC; DERMATOLOGY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PRESCHOOL CHILD; PRIMARY HEALTH CARE; TRENDS;

ADRENAL CORTEX HORMONES; CALCINEURIN INHIBITORS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMORBIDITY; DERMATITIS, ATOPIC; DERMATOLOGY; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MUTATION; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PRIMARY HEALTH CARE;

EID: 84904503432     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000109     Document Type: Review

References (47)

1. Horii KA, Simon SD, Liu DY, Sharma V. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics 2007; 120:e527-e534. (Pubitemid 47358264)
2. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011; 131:67-73.
3. Valeant Pharmaceuticals North America. Data on file, 2012.
4. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92:44-47.
5. Rudzki E, Samochocki Z, Rebandel P, et al. Frequency and significance of the major and minor features of Hanifin and Rajka among patients with atopic dermatitis. Dermatology 1994; 189:41-46. (Pubitemid 24126370)
6. Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003; 49:1088-1095. (Pubitemid 37475483)
7. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004; 69:548-556. (Pubitemid 38176273)
8. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: Section 1 Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70:338-351.
9. Levin J, Friedlander SF, Del Rosso JQ. Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol 2013; 6:16-22.
10. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129:1892-1908.
11. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365:1315-1327.
12. Brown SJ, McLean WH. One remarkable molecule: filaggrin. JInvest Dermatol 2012; 132:751-762.
13. Margolis DJ, Kim B, Apter AJ, et al. Thymic stromal lymphopoietin variation. Filaggrin loss of function, and the persistence of atopic dermatitis. JAMA Dermatol 2014; 150:254-9.
14. Wang WL, Li HY, Zhang MS, et al. Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases. Int Arch Allergy Immunol 2013; 160:18-26.
15. Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol 2013; 133:1752-1759.
16. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112 (6 Suppl):S118-S127. (Pubitemid 37550028)
17. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007; 120:565-569. (Pubitemid 47334839)
18. Zhang Z, Hener P, Frossard N, et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci U S A 2009; 106:1536-1541.
19. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol 2009; 7:e1000067.
20. Han H, Xu W, Headley MB, et al. Thymic stromal lymphopoietin (TSLP)-mediated dermal inflammation aggravates experimental asthma. Mucosal Immunol 2012; 5:342-351.
21. Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy 2014; 69:17-27.
22. Deckert S, Kopkow C, Schmitt J. Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy 2014; 69:37-45.
23. Polanczyk G, Silva de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164:942-948. (Pubitemid 46972911)
24. Schmitt J, Romanos M, Schmitt NM, et al. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA 2009; 301:724-726.
25. Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a largepopulation-based sample. J Epidemiol Community Health 2010;64:269-273.
26. Tsai JD, Chang SN, Mou CH, et al. Association between atopic diseases and attention-deficit/hyperactivity disorder in childhood: a population-based case-control study. Ann Epidemiol 2013; 23:185-188.
27. Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review Allergy 2010; 65:1506-1524.
28. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013; 131:428-433.
29. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142:931-936. (Pubitemid 30304603)
30. Crespi HG. Topical corticosteroid therapy for children: alclometasone dipro-pionate cream 005%. Clin Ther 1986; 8:203-210. (Pubitemid 17074644)
31. Paller AS, Nimmagadda S, Schachner L, et al. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dermatol 2003; 48:569-577. (Pubitemid 36397021)
32. Eichenfield LF, Basu S, Calvarese B, Trancik RJ. Effect of desonide hydrogel 005% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol 2007; 24:289-295. (Pubitemid 46848955)
33. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013; 15:303-310.
34. Frankel HC, Qureshi AA. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 2012; 13:113-123.
35. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330:516.
36. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009; 54:76-87.
37. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 2013; 14:163-178.
38. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008; 122:812-824.
39. Barnes TM, Greive KA. Use of bleach baths for the treatment of infected atopic eczema. Australas J Dermatol 2013; 54:251-258.
40. Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol 2013; 40:874-80.
41. Thomas H Leung, Lillian F Zhang, Jing Wang, et al. Topical hypochlorite ameliorates NF-kB-mediated skin diseases in mice. J Clin Invest 2013; 123:5361-5370. doi:10.1172/JCI70895.
42. Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002; 119:166-173. (Pubitemid 35304406)
43. Wollenberg A, Räwer HC, Schauber J. Innate immunity in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41:272-281.
44. Mihm MC Jr, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976; 67:305-312.
45. Williams HC. Preventing eczema flares with topical corticosteroids or tacro-limus: which is best? Br J Dermatol 2011; 164:231-233.
46. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164:415-428.
47. Otsuka A, Doi H, Egawa G, et al. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol 2014; 133:139-146; e10.